Literature DB >> 12531792

PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A.

Eun-Yi Moon1, Adam Lerner.   

Abstract

Chronic lymphocytic leukemia (CLL) cells, but not peripheral blood T cells, undergo apoptosis following treatment with inhibitors of type 4 cyclic nucleotide phosphodiesterase (PDE4), a process that correlates dose dependently with elevation of adenosine 3',5'-cyclic monophosphate (cAMP) in leukemic cells. We show that treatment of CLL cells with rolipram, a prototypic PDE4 inhibitor, and forskolin, an adenylate cyclase activator, induces mitochondrial depolarization, release of cytochrome c into the cytosol, caspase-9 and -3 activation, and cleavage of poly(adenosine diphosphate [ADP]-ribose)polymerase. Inhibitors of caspase-9, but not caspase-8, block rolipram/forskolin-induced CLL apoptosis. In a subset of CLL patients, B-cell lymphoma 2 (Bcl-2)-associated death promoter homolog (Bad), a proapoptotic Bcl-2 family member that when phosphorylated on specific serine residues is sequestered in the cytosol by 14-3-3, was dephosphorylated at Ser112 following rolipram/forskolin treatment of leukemic cells. Rolipram/forskolin treatment also induced Bad to accumulate in CLL heavy-membrane fractions, consistent with Bad translocation to mitochondria. To determine the mechanism for rolipram/forskolin-induced Bad dephosphorylation, we examined CLL phosphatase activity. Rolipram/forskolin treatment augmented protein phosphatase 2A (PP2A) activity, as well as levels of immunoreactive PP2A catalytic subunit. Treatment of CLL cells with a concentration of okadaic acid (5 nM) that selectively inhibits PP2A, reduced both rolipram/forskolin-induced mitochondrial cytochrome c release and mitochondrial depolarization. Okadaic acid restored Bad Ser112 phosphorylation and Bad association with 14-3-3 in rolipram/forskolin-treated CLL cells. These results suggest that PDE4 inhibitors may induce CLL apoptosis by activating PP2A-induced dephosphorylation of proapoptotic BH3-only Bcl-2 family members such as Bad.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12531792     DOI: 10.1182/blood-2002-10-3208

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

Review 1.  Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.

Authors:  Adam Lerner; Paul M Epstein
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

2.  Glial restricted precursor cell transplant with cyclic adenosine monophosphate improved some autonomic functions but resulted in a reduced graft size after spinal cord contusion injury in rats.

Authors:  Yvette S Nout; Esther Culp; Markus H Schmidt; C Amy Tovar; Christoph Pröschel; Margot Mayer-Pröschel; Mark D Noble; Michael S Beattie; Jacqueline C Bresnahan
Journal:  Exp Neurol       Date:  2010-10-30       Impact factor: 5.330

3.  A novel Epac-Rap-PP2A signaling module controls cAMP-dependent Akt regulation.

Authors:  Kyoungja Hong; Liguang Lou; Sandhya Gupta; Fernando Ribeiro-Neto; Daniel L Altschuler
Journal:  J Biol Chem       Date:  2008-06-12       Impact factor: 5.157

Review 4.  Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development.

Authors:  William G Robichaux; Xiaodong Cheng
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

5.  Repositioning antispasmodic drug Papaverine for the treatment of chronic myeloid leukemia.

Authors:  Phani Krishna Parcha; Sailu Sarvagalla; Cheemala Ashok; S J Sudharshan; Madhu Dyavaiah; Mohane Selvaraj Coumar; Baskaran Rajasekaran
Journal:  Pharmacol Rep       Date:  2021-01-03       Impact factor: 3.024

6.  Increased expression of the pro-apoptotic protein BIM, a mechanism for cAMP/protein kinase A (PKA)-induced apoptosis of immature T cells.

Authors:  Alexander C Zambon; Andrea Wilderman; Angela Ho; Paul A Insel
Journal:  J Biol Chem       Date:  2011-08-01       Impact factor: 5.157

7.  FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

Authors:  Paolo Neviani; Ramasamy Santhanam; Joshua J Oaks; Anna M Eiring; Mario Notari; Bradley W Blaser; Shujun Liu; Rossana Trotta; Natarajan Muthusamy; Carlo Gambacorti-Passerini; Brian J Druker; Jorge Cortes; Guido Marcucci; Ching-Shih Chen; Nicole M Verrills; Denis C Roy; Michael A Caligiuri; Clara D Bloomfield; John C Byrd; Danilo Perrotti
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

Review 8.  Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies.

Authors:  Jeffrey D Cooney; Ricardo C T Aguiar
Journal:  Blood       Date:  2016-10-18       Impact factor: 22.113

9.  Chronic lymphocytic leukemia and B and T cells differ in their response to cyclic nucleotide phosphodiesterase inhibitors.

Authors:  John A Meyers; Derrick W Su; Adam Lerner
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

10.  A high density assay format for the detection of novel cytotoxic agents in large chemical libraries.

Authors:  David Shum; Constantin Radu; Earl Kim; Muriel Cajuste; Yufang Shao; Venkatraman E Seshan; Hakim Djaballah
Journal:  J Enzyme Inhib Med Chem       Date:  2008-12       Impact factor: 5.051

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.